Ms-pharm Spółka z Ograniczoną Odpowiedzialnością (KRS 0000592964, NIP 7831735222) is a Polish company, headquartered in Szczecin, Zachodniopomorskie voivodeship. Ms-pharm operates in: Activities of head offices (PKD 70.10.Z). Industry: Consulting and management. The company has been listed in the National Court Register since December 21, 2015. Ms-pharm's most recently reported net revenue was 0 PLN for 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Ms-pharm
Identity
- Name
- Ms-pharm Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- December 21, 2015
- Registry status as of
- June 1, 2026
- Latest entry
- June 1, 2026
- Founding act
- 06.11.2015 R., NOTARIUSZ KATARZYNA BARTKOWIAK, KANCELARIA NOTARIALNA W GOLENIOWIE, REP. A NR 4842/2015
Articles of association history (2)
- November 6, 2015: 06.11.2015 R., NOTARIUSZ KATARZYNA BARTKOWIAK, KANCELARIA NOTARIALNA W GOLENIOWIE, REP. A NR 4842/2015
- February 5, 2020: 05.02.2020 R., REP. A NR 277/2020, KANCELARIA NOTARIALNA W ŁODZI, NOTARIUSZ PIOTR KRÓL - ZMIENIONO: § 1 UST. 3, § 11 UST. 7, § 12 UST. 4 I 5 UMOWY SPÓŁKI.
Activities
Other activities
Address and contact
- Address
- UL. KOMUNY PARYSKIEJ, 40, 71-680, SZCZECIN, POLSKA
- Voivodeship
- ZACHODNIOPOMORSKIE
- District
- SZCZECIN
- BIURO@MSPHARM.COM.PL
- Website
- WWW.MSPHARM.COM.PL
- E-delivery address
- AE:PL-46677-42158-RHFJR-30
Risk and payment profile - Ms-pharm
Credibility rating
64.7 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
10
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/10 yrs
Board changes
5
5/10 yrs
PKD changes
0
0/10 yrs
Name changes
0
0/10 yrs
Data from 10 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: C (65/100)
Trend: deteriorating (-2.1 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2018–2024
Current: 5.6 K PLN
Safe: 2.5 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Ms-pharm
Founded
December 21, 2015
10 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
SZCZECIN
ZACHODNIOPOMORSKIE
Primary PKD
70.10.Z
Activities of head offices
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
3 people
Filed years
7 years
2018–2024 · profitable: 5/7
Registry entries
36
latest: June 1, 2026
Revenue
0 PLN
2024
Net profit
17.8 K PLN
2024
Assets
105.6 K PLN
2024
Equity
104.4 K PLN
2024
Valuation
139.8 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Ms-pharm.
No ratings
Related articles
News
Agora in 2026: return to dividends after 6 years (PLN 0.25), EBITDA of PLN 148m, PLN 200m strategic target
Agora S.A. - the Warsaw-based media holding (Gazeta Wyborcza, the Helios cinema chain, Radio TOK FM and Złote Przeboje, AMS outdoor, Yieldbird) - paid its first dividend in six years (PLN 0.25 per share, PLN 11.65m in total). The 2026–2029 strategy targets a cumulative PLN 2.50 per share in dividends and lifts EBITDA from PLN 148m to PLN 200m.
News
Archicom: a PLN 1.80 per share dividend recommendation after a record 2025 - 2,847 apartments sold, three times the market growth
Wrocław-based Archicom S.A. (KRS 0000555355) closed 2025 with revenue of PLN 961.7 m (+30% YoY), standalone net profit of PLN 229.9 m and 2,847 apartments sold (+30% YoY versus market +9.3%). The board recommends a PLN 1.80 per share dividend (PLN 105.3 m); the final decision rests with the AGM (scheduled for July 2026). The 2026 target: 3,200-3,500 units plus a debut in the Tricity. The first full year under Echo Investment control (74.04%) after the 2023 integration.
